India's Lupin Ltd. announced the U.S. launch of Voriconazole to treat fungal infections in patients 12 years old and above.

The U.S.-FDA approved generic was launched in 50 mg and 200 mg tablets and 40 mg/ml oral suspension. Voriconazole will compete with PF Prism CV's Vfend tablets, which had U.S. sales of $81 million in the 12 months ended September and Vfend oral suspension which also generated $15.2 million during the same period.